Clinical Trial Update: A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas [Phase 3]

View source ↗

Summary

Phase 3 results are reported for relacorilant in patients with cortisol-secreting adrenal adenomas causing hypercortisolism, evaluating its efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• Relacorilant (relacorilant)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Hypercortisolism | Phase 3 | Status: COMPLETED | Results posted: 2025-08-03